News

News

Aflibercept Biosimilar Updates: SCD-411 FDA aBLA Acceptance; AVT06 Settlement Agreement

by Robert S. Schwartz, Ph.D.
December 24, 2025

On December 3, 2025, Fresenius Kabi and SamChunDang Pharm announced the FDA acceptance of their aBLA for SCD-411 (aflibercept), a proposed biosimilar of Regeneron’s EYLEA® (aflibercept).  Under their licensing agreement SamChunDang developed the biosimilar candidate and Fresenius Kabi will exclusively commercialize it in the U.S.  Fresenius Kabi and SamChunDang have challenged Regeneron’s U.S. Patent Nos. 11,084,865 (IPR2025-01268) and 10,828,345 (IPR2025-01269) (previously reported Fresenius Kabi Files Two EYLEA® IPRs Prior to aBLA Filing Announcement).  The IPRs are awaiting institution decisions.

On December 19, 2025, Alvotech and Teva announced a settlement agreement with Regeneron relating to AVT06 (aflibercept), their proposed EYLEA® biosimilar.  The agreement allows for the launch of AVT06 in the fourth quarter of 2026, or earlier under certain undisclosed circumstances, subject to FDA approval.  Alvotech has challenged Regeneron’s U.S. Patent No. 12,168,036 in PGR2025-00085.  This PGR remains pending and is awaiting an institution decision.

Regeneron has settled lawsuits with numerous other biosimilar applicants and provided market entry dates in 2026, including Yesafili™ (aflibercept-jbvf) in the second half of 2026 (previously reported Regeneron and Biocon Settle Litigation over EYLEA® Biosimilar Yesafili™), Enzeevu™ (aflibercept-abzv) and Ahzantive® (aflibercept-mrbb) in the fourth quarter of 2026 (previously reported Regeneron Settles Litigations with Sandoz and Formycon over EYLEA® Biosimilars Enzeevu™ and Ahzantive®), and Eydenzelt® (aflibercept-boav) as early as December 31, 2026 (previously reported Regeneron Settles Litigations with Celltrion over EYLEA® Biosimilar Eydenzelt®).

SCD-411 and AVT06 are the only publicly announced aBLAs for EYLEA® biosimilars currently pending with the FDA.  To date, the FDA has approved six EYLEA® biosimilars and one, Pavblu™ (aflibercept-ayyh), has launched at-risk (previously reported Amgen Launches Pavblu™ as the First EYLEA® Biosimilar in the U.S.).

Regeneron reported EYLEA® U.S. sales of $4.77 billion in FY2024.

For more information on these and other biosimilars, please visit BiologicsHQ.

 

_____________________________________________________

The author would like to thank April Breyer Menon for her contributions to this article.

    Methodology

    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

    Disclaimer

    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates

      captcha